HOME >> BIOLOGY >> NEWS
Select research highlights from current AACR journals

From the September 1 issue of Cancer Research:

  • Aberrations in the receptor protein dystroglycan may lead to either muscular dystrophy or the development of carcinomas. Whereas several molecular defects in muscle disease have been characterized, little is known about such changes in carcinoma cells. Singh et al. identified multiple post-translational modifications that modulate dystroglycan function in these aberrant cells. Novel defects in carcinoma cells arising in this important cell adhesion molecule are similar to defects recently identified in muscular dystrophies. The research was conducted at the Lawrence Berkley National Laboratories, Berkley, Calif,; the University of Iowa, Iowa City, Iowa; and California Pacific Medical Center Research Institute, San Francisco, Calif.

    Among research findings featured in the September 1 issue of Clinical Cancer Research are:

  • Heat therapy increases the efficacy of tumor treatment with melphalan, an alkylating agent used in cancer therapy for ovarian cancer and certain bone marrow tumors. In rat models for fibrosarcomas, Abdel-Wahab et al. documented that heat treatment with warm water heightened the response of tumors to high doses of melphalan. The effect was synergistic, but not related to heat-promoted increased uptake of the drug. The studies were conducted at Duke University Medical Center, Durham, N.C.

  • Two inhibitors of steroid synthesis used to treat hormone-dependent breast cancer in postmenopausal women pack a significant beneficial side effect in laboratory animals. Exemestane and letrozole was shown to significantly prevent bone loss, enhance bone mechanical strength and lower serum cholesterol levels. The inhibitor drugs act by interfering with estrogen synthesis and depleting estrogen concentrations in the blood, according to the study by Goss et al., conducted at the University of Toronto, Toronto, Ontario.

    Included among the articles pub
    '"/>



  • Contact: Russell Vanderboom, PhD
    vanderboom@aacr.org
    215-440-9300
    American Association for Cancer Research
    1-Sep-2004


    Page: 1 2

    Related biology news :

    1. Selected estrogen compounds modify risks of vein clotting, a response to hormone replacement theraphy
    2. News briefing: Foods of the future: Selecting and designing foods for a healthy 2025
    3. Aldo Leopold Leadership Program Selects First Cohort
    4. Genetic Screening May Be Tool For Selecting Cancer Treatment, Research Suggests
    5. Ligand Scientists Discover Tissue-Selective Female Hormone Mimics
    6. Life-Saving Dr. Mueller Selected To Get Top Sports Medicine Award
    7. Leader in cancer treatment and prevention research honored
    8. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
    9. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
    10. Belgian researchers explore revolutionary approach to angiogenesis
    11. Award winning researchers reveal potential new role for Glivec

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:7/10/2020)... , ... July 09, 2020 , ... Today CJ BIO ... which will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, ... Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during ...
    (Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a ... purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture ... facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible ...
    (Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
    Breaking Biology News(10 mins):
    (Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
    (Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World ... Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, ... an elite awards program, highlighting outstanding examples of how technology innovations and strategic ...
    (Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
    (Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... cancer, today announced the company has entered a license agreement with Roswell Park ... Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical ...
    Breaking Biology Technology:
    Cached News: